The healthcare sector is supported by some very strong fundamentals including ongoing demographic changes, continued innovation across pharma devices and diagnostics, a widening of available treatments and the application of technology across traditional pathways.
As a result, a multitude of businesses are crossing into the healthcare area including consulting, technology and business services in concerted efforts to capitalise on the segment’s potential.
In the UK, the need to keep improving outcomes from National Health Service spending with a limited budget will drive adoption of technologies which improve service delivery and outcomes. The recent pandemic will accelerate adoption enabling remote access to medical professionals, changing access points for patients and improving utilisation of healthcare professionals amongst other things.
At Cavendish, we work closely with companies across the Pharma, Life Sciences, MedTech, Diagnostics, Healthcare Services and the Health and Social Care segments advising them on making the most of the opportunities available.
Cavendish announces the sale of Avicenna Holdings to Juno Health
Cavendish advised on the successful acquisition of Avicenna Holdings Limited by Juno Health Limited. Avicenna comprises 21 pharmacies, as well as a buying group operation serving more than 1,000 independent pharmacies.
Recent deals for Healthcare
Rapidscan Pharm Solutions Inc
Venture Life Group Plc
DB Ashbourne Limited
Barbican Dental Care
Meet our experts
Cavendish’s success is based on the wealth of experience of our people. We have a team of professionals with expertise across a wide variety of sectors, deal sizes, and transaction types.
‘finnCapCavendish have great international connections and were able to bring an Australian buyer in the patient flow software sector to us. Their tenacity and understanding of the deal dynamics enabled us to run a smooth process and sell Extramed to a strategic buyer.’
“The team at Cavendish have done a fantastic job advising the Board of Zenith. They were confident that there would be strong overseas interest in the business and they managed that interest extremely professionally. We are delighted with the outcome and look forward to the next chapter for Zenith.”
“The Cavendish Team, led by Michael Jewell, did an excellent job managing a well-orchestrated auction process and ensuring the smooth closing of the transaction in a timely manner. They were professional and easy to deal with throughout and committed to achieving a successful outcome for the shareholders.”
I am very pleased to have found such a complementary match in Venture Life, a highly successful consumer healthcare group with a reputation for accelerating the growth of the brands it acquires.
The resources and expertise of Venture Life will see Periproducts on a trajectory of rapid growth under the guidance of a proven management team, through enhanced marketing opportunities, new product development and, crucially, access to a substantial number of export markets.The Cavendish team were of great assistance throughout the sale process and in particular finding us the most fitting acquirer, helped by their strong networks in healthcare and their understanding of the oral care market.
“We are delighted to partner with Bridgepoint who will help take MVF to the next level. Bridgepoint has proved to be the perfect match for MVF because they understand the company vision and culture and have the financial capability and international reach to support the continued growth of the business.
We made absolutely the right choice in appointing Cavendish. Michael Jewell and the team were instrumental in getting us the deal we wanted. I would have no hesitation in recommending them to anyone thinking about a sales process.”
I wanted to express my personal thanks to you for all your efforts in achieving a successful sale of Yorktest. I never knew how stressful and complex the sale process could be. I really do appreciate your finding a good deal in quite difficult circumstances.
Cavendish’s Exit Review allowed us to align and mobilize all stakeholders on the key priorities that have the most impact on valuation over a 6-18 month period – a very valuable exercise.